Cleveland BioLabs invited to countermeasure symposium
The symposium, entitled "Development of Radiation Medical Countermeasures for Licensure: Lessons Learned & Paths Forward," was hosted by the U.S. Biomedical Advanced Research and Development Authority and the U.S. National Institute of Allergy and Infectious Diseases.
The meeting featured product developers like CBLI, as well as U.S. government representatives from BARDA, NIAID, the U.S. Food and Drug Administration, the U.S. Department of Defense, and the U.S. Centers for Disease Control and Development.
The aim of the two-day meeting, held on January 24 and 25, was to share recently collected data and serve as a forum to discuss the variety of challenges involved in the development of products to mitigate acute radiation syndrome and the delayed effects of radiation exposure.
The attendees sought to harmonize their understanding of how to use animal modeling to more accurately test their products. It also gave attendees an opportunity to discuss issues with regulatory authorities and the broader development community.
Cleveland BioLabs is a biotechnology company that focuses on developing compounds that have oncology applications and are capable of mitigating radiation injury. The company's lead compound is being developed both as a cancer treatment and a radiation countermeasure.